IL271430A - Methods to treat opioid use disorder - Google Patents
Methods to treat opioid use disorderInfo
- Publication number
- IL271430A IL271430A IL271430A IL27143019A IL271430A IL 271430 A IL271430 A IL 271430A IL 271430 A IL271430 A IL 271430A IL 27143019 A IL27143019 A IL 27143019A IL 271430 A IL271430 A IL 271430A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- use disorder
- opioid use
- treat opioid
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762521121P | 2017-06-16 | 2017-06-16 | |
US201762572331P | 2017-10-13 | 2017-10-13 | |
US201762572996P | 2017-10-16 | 2017-10-16 | |
US201762598338P | 2017-12-13 | 2017-12-13 | |
US201862632995P | 2018-02-20 | 2018-02-20 | |
US201862656216P | 2018-04-11 | 2018-04-11 | |
US201862680935P | 2018-06-05 | 2018-06-05 | |
PCT/IB2018/000770 WO2018229551A2 (en) | 2017-06-16 | 2018-06-15 | Methods to treat opioid use disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
IL271430A true IL271430A (en) | 2020-01-30 |
Family
ID=63407480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL271430A IL271430A (en) | 2017-06-16 | 2019-12-15 | Methods to treat opioid use disorder |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3638240A2 (en) |
AU (1) | AU2018283724B2 (en) |
IL (1) | IL271430A (en) |
NZ (1) | NZ760033A (en) |
WO (1) | WO2018229551A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016071767A1 (en) | 2014-11-07 | 2016-05-12 | Indivior Uk Limited | Buprenorphine dosing regimens |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005249274B2 (en) | 2004-06-04 | 2011-02-24 | Camurus Ab | Liquid depot formulations |
EP1843751B1 (en) | 2005-01-21 | 2020-09-30 | Camurus Ab | Pharmaceutical lipid compositions |
US8975270B2 (en) | 2010-06-08 | 2015-03-10 | Rb Pharmaceuticals Limited | Injectable flowable composition comprising buprenorphine |
GB2481018B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
WO2016071767A1 (en) * | 2014-11-07 | 2016-05-12 | Indivior Uk Limited | Buprenorphine dosing regimens |
AU2016349111A1 (en) | 2015-11-04 | 2018-05-17 | Indivior Uk Limited | Quantification of drugs in biological samples |
-
2018
- 2018-06-15 NZ NZ760033A patent/NZ760033A/en unknown
- 2018-06-15 WO PCT/IB2018/000770 patent/WO2018229551A2/en active Application Filing
- 2018-06-15 AU AU2018283724A patent/AU2018283724B2/en active Active
- 2018-06-15 EP EP18762131.3A patent/EP3638240A2/en active Pending
-
2019
- 2019-12-15 IL IL271430A patent/IL271430A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018229551A2 (en) | 2018-12-20 |
EP3638240A2 (en) | 2020-04-22 |
WO2018229551A3 (en) | 2019-02-14 |
AU2018283724A1 (en) | 2020-01-16 |
NZ760033A (en) | 2023-02-24 |
AU2018283724B2 (en) | 2021-08-19 |
AU2018283724A2 (en) | 2020-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285151B1 (en) | Methods of treating fgf21-associated disorders | |
ZA201705673B (en) | Methods for treating skin | |
IL258931A (en) | Therapeutic compounds and methods | |
HK1259336A1 (en) | Methods for treating myeloproliferative disorders | |
ZA201701491B (en) | Methods and therapeutic combinations for treating tumors | |
IL250677A0 (en) | Treatment of cancers using anti-nkg2a agents | |
GB201701673D0 (en) | Methods of well treatment | |
HK1256036A1 (en) | Methods for treating myeloproliferative disorders | |
AU362358S (en) | Pet treat | |
EP2970317A4 (en) | Pyrimido-diazepinone compounds and methods of treating disorders | |
HK1244681A1 (en) | Therapeutic combinations and methods for treating neoplasia | |
PL3215219T3 (en) | Skin treatment system | |
IL293712A (en) | Methods of treating mild brain injury | |
IL252296A0 (en) | Methods of treating multiple sclerosis | |
HK1220209A1 (en) | Methods of treating acute kidney injury | |
HK1215164A1 (en) | Treatment methods | |
HK1259445A1 (en) | Combinations to treat cancer | |
GB201416832D0 (en) | Methods of treatment | |
IL250658A0 (en) | Methods of treating mild brain injury | |
HK1249866A1 (en) | Methods of treatment with taselisib | |
IL271430A (en) | Methods to treat opioid use disorder | |
SG11201700059WA (en) | Therapeutic agent for keratoconjunctive disorder | |
GB201400311D0 (en) | Treating Susceptibility | |
GB201512139D0 (en) | Methods of treatment | |
GB201608599D0 (en) | Treatment of opioid tollerence |